Suprecur 0.15 mg/ dose ノルウェー - ノルウェー語 - Statens legemiddelverk

suprecur 0.15 mg/ dose

sanofi-aventis norge (3) - buserelinacetat - nesespray, oppløsning - 0.15 mg/ dose

Yesafili 欧州連合 - ノルウェー語 - EMA (European Medicines Agency)

yesafili

viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - Øyemidler - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.

Ioa 欧州連合 - ノルウェー語 - EMA (European Medicines Agency)

ioa

n.v. organon - nomegestrol acetat, estradiol - prevensjon - sex hormoner og modulatorer av genital systemet, - oral prevensjon.

Zoely 欧州連合 - ノルウェー語 - EMA (European Medicines Agency)

zoely

theramex ireland limited - nomegestrol acetat, estradiol - prevensjon - sex hormoner og modulatorer av genital systemet, - oral contraception,.

Plegridy 欧州連合 - ノルウェー語 - EMA (European Medicines Agency)

plegridy

biogen netherlands b.v. - peginterferon beta-la - multippel sklerose - immunostimulants, - behandling av tilbakefallende remitterende multippel sklerose hos voksne pasienter.

Trimbow 欧州連合 - ノルウェー語 - EMA (European Medicines Agency)

trimbow

chiesi farmaceutici s.p.a. - beclometasone dipropionate, formoterol fumarate dihydrat, glycopyrronium bromide - lungesykdom, kronisk obstruktiv - legemidler for obstruktive sykdommer i luftveiene, - maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year. copdmaintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5. asthmamaintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.

Amlodipin Sandoz 5 mg ノルウェー - ノルウェー語 - Statens legemiddelverk

amlodipin sandoz 5 mg

sandoz a/s - amlodipinbesilat - tablett - 5 mg

Amlodipin Sandoz 10 mg ノルウェー - ノルウェー語 - Statens legemiddelverk

amlodipin sandoz 10 mg

sandoz a/s - amlodipinbesilat - tablett - 10 mg

Carboplatin Fresenius Kabi 10 mg/ ml ノルウェー - ノルウェー語 - Statens legemiddelverk

carboplatin fresenius kabi 10 mg/ ml

fresenius kabi norge as - karboplatin - konsentrat til infusjonsvæske, oppløsning - 10 mg/ ml

Dexmopet vet 0.5 mg/ ml ノルウェー - ノルウェー語 - Statens legemiddelverk

dexmopet vet 0.5 mg/ ml

vetpharma animal health, s.l. - deksmedetomidinhydroklorid - injeksjonsvæske, oppløsning - 0.5 mg/ ml